CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $149.47M, lower than 95% of all stocks globally
- PositionReturn on equity is 126.2%, higher than 95% of its Biotechnology peers (median -21.7%)
- Interpretations5 currently firing — 5
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
149.47MUSDvs all stocks (USD)
Trailing P/E
0.0247xvs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.47xvs all stocks
52-Week Change
-43.11%vs all stocks
Market Capitalization
149.47MUSDvs all stocks (USD)
Enterprise Value
144.48MUSDvs all stocks (USD)
Trailing P/E
0.0247xvs Biotechnology peers
Forward P/E
-0.8079xvs Biotechnology peers
Price to Book (MRQ)
0.0773xvs Biotechnology peers
Enterprise to EBITDA
-9.85xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-0.80%vs Biotechnology peers
Return on Equity (TTM)
126.17%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-14.67MUSDvs all stocks (USD)
Net Income (TTM)
1.24BUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-10.42MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-1.74BUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 9, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-15.00MUSDvs all stocks (USD)
Pre-tax Income
1.62BUSDFY2025 · Dec 31, 2025Income Tax Expense
382.65MUSDFY2025 · Dec 31, 2025Net Income
1.24BUSDFY2025 · Dec 31, 2025EBIT
-15.00MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-1.65BUSDFY2025 · Dec 31, 2025Research & Development
9.20MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
5.68MUSDFY2025 · Dec 31, 2025Other Operating Expenses
111.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Income
792.00KUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.24BUSDFY2025 · Dec 31, 2025Operating Cash Flow
1.62BUSDFY2025 · Dec 31, 2025Free Cash Flow
1.62BUSDDerived from operating cash flow minus capital expenditure. This filing charges 332K of depreciation against 67K of capital expenditure, and its own free-cash-flow line reads -10.48M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.37MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.24BUSDFY2025 · Dec 31, 2025Depreciation & Amortization
332.00KUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
382.65MUSDFY2025 · Dec 31, 2025Stock-based Compensation
1.78MUSDFY2025 · Dec 31, 2025Other Non-cash Items
263.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.00MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-206.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-67.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-44.00MUSDFY2025 · Dec 31, 2025Sale of Investments
42.74MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.32MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
10.38MUSDFY2025 · Dec 31, 2025Shares Outstanding
237.38MSharesUpdated Jul 9, 2026Float Shares
57.72MSharesUpdated Jul 9, 2026Shares Short
417.77KSharesUpdated Jul 9, 2026Short Ratio
1.19daysvs all stocks
Short % of Shares Outstanding
0.17%vs all stocks
% Held by Insiders
85.26%vs all stocks
% Held by Institutions
1.51%vs all stocks
Total Cash (MRQ)
5.75MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.0240USDUpdated Jul 9, 2026Total Debt (MRQ)
641.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0003xvs Biotechnology peers
Current Ratio (MRQ)
193.24xvs Biotechnology peers
Book Value per Share (MRQ)
8.15USDUpdated Jul 9, 2026Total Assets
2.33BUSDvs all stocks (USD)
Total Current Assets
1.74BUSDFY2025 · Dec 31, 2025Total Liabilities
392.05MUSDFY2025 · Dec 31, 2025Total Non-current Assets
583.82MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
383.03MUSDFY2025 · Dec 31, 2025Total Current Liabilities
9.02MUSDFY2025 · Dec 31, 2025Cash
1.58MUSDFY2025 · Dec 31, 2025Cash Equivalents
314.00KUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.89MUSDFY2025 · Dec 31, 2025Other Short-term Investments
3.86MUSDFY2025 · Dec 31, 2025Accounts Payable
3.81MUSDFY2025 · Dec 31, 2025Short-term Debt
258.00KUSDFY2025 · Dec 31, 2025Long-term Debt
383.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
28.73MUSDFY2025 · Dec 31, 2025Retained Earnings
1.11BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.93BUSDvs all stocks (USD)
52-Week Low
0.6110USDUpdated Jul 9, 202652-Week High
2.10USDUpdated Jul 9, 202652-Week Change
-43.11%vs all stocks
Beta
1.47xvs all stocks
50-Day MA
0.7930USDUpdated Jul 9, 2026200-Day MA
0.9674USDUpdated Jul 9, 2026Avg 10-Day Volume
292.55KSharesUpdated Jul 9, 2026Avg 30-Day Volume
366.38KSharesUpdated Jul 9, 2026Diluted EPS (TTM)
25.48USDUpdated Jul 9, 2026Other Income / Expense
1.63BUSDFY2025 · Dec 31, 20255 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
How does this company use capital?
Diagnostic
Underinvestment Cash Flow
Less of its cash flow goes to capex than at most of its peers, on an asset base already largely written down.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 126.2%, higher than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: 1.26Industry median: -0.22Industry P95: 0.23Peers compared: 261
Current ratio is 193.24×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 193.236Industry median: 5.64Industry P95: 23.02Peers compared: 261
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
P/E ratio is 0.02×, lower than 95% of its Biotechnology peers (median 32.39×)Notable
P/E ratio: 0.02Industry median: 32.39Industry P5: 5.49Peers compared: 261
Price-to-book is 0.08×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 0.08Industry median: 2.97Industry P5: 1.03Peers compared: 261
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 1,235,527,936Operating Cash Flow (USD, TTM): -10,416,000
Financial Health
Altman Z-Score 1.77: grey zoneSignificant
Altman Z-Score: 1.77
Low earnings qualitySignificant
Earnings Quality Score: -0.61
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $149.47M, lower than 95% of all stocks globallySignificant
Market cap (USD): 149,474,313Global P5: 269,387,740.27
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Levered free cash flow is -$1.74B, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -1,737,054,976Global P5: -219,013,500
Companies that share the same coordination system — how they create, deliver, or capture value.
Yungjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
HLB Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
EKF Diagnostics Holdings plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
S Biomedics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Chill Brands Group Plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Graphy Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sensorion SA
Tier 1ProductionApproval-Gated PipelineRuleRisk
Mycenax Biotech Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Futurechem Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Journey Medical Corp
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Liaoning Xinde New Material Co. Ltd.
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedLow-Leverage Liquidity Configuration
Dongguan Tarry Electronics Co., Ltd.
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedLow-Leverage Liquidity Configuration
Suzhou Maxwell Technologies Co., Ltd.
3 interpretationsFCF Ratios ElevatedPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated